Prognostic and predictive biomarker analysis in mCRC KRAS wild type patients treated in first line with Erbitux (Cetixumab) in combination with standard chemotherapy in daily clinical practice in Belgium. 01/09/2013 - 31/08/2017

Abstract

This project represents a formal research agreement between UA and on the other hand UZA. UA provides UZA research results mentioned in the title of the project under the conditions as stipulated in this contract.

Researcher(s)

Research team(s)

    Project type(s)

    • Research Project